# Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

> **NCT01457846** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 960 (actual)

## Conditions studied

- Gastro-oesophageal Junction Cancer
- Gastric Cancer

## Interventions

- **DRUG:** AZD4547
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01457846
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-08
- **Final completion:** 2015-02
- **Target enrollment:** 960 (ACTUAL)
- **Last updated:** 2017-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457846, "Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT01457846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*